Helen Torley - 06 Jul 2021 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role: President and CEO, Director
Signature: /s/ James R. Oehler as attorney-in-fact for Helen Torley
Issuer symbol: HALO
Transactions as of: 06 Jul 2021
Net transactions value: -$2,298,650
Form type: 4
Filing time: 06 Jul 2021, 18:09:05 UTC
Previous filing: 07 Jun 2021
Next filing: 10 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HALO	Common Stock	Options Exercise	$733,000	+50,000	+9.3%	$14.66	587,160	06 Jul 2021	Direct	F1
transaction	HALO	Common Stock	Sale	$2,298,650	-50,000	-8.5%	$45.97	537,160	06 Jul 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HALO	Option to Purchase Common Stock	Options Exercise	$733,000	-50,000	-12%	$14.66	350,000	06 Jul 2021	Common Stock	50,000	$14.66	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1.
F2	Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.40 to $46.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3	Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014.